OmniAb, Inc. announced that Director Sunil Patel passed away suddenly last week. Sunil Patel was appointed to OmniAb?s Board in November 2022 when OmniAb was spun-out of Ligand Pharmaceuticals as an independent, publicly-traded company, and previously served on the Ligand Pharmaceuticals Board of Directors since 2010. With more than 25 years of senior management and R&D experience in the biotechnology industry, Mr. Patel most recently worked as an independent consultant to biotechnology companies advising on strategy and corporate development initiatives.

Previously, he served in executive roles at OncoMed Pharmaceuticals, Inc., including Executive Vice President and Chief Financial Officer. He held senior management positions in corporate development, marketing and strategy with BiPar Sciences, Inc., Allos Therapeutics, Inc., Connetics, Abgenix, Inc. and Gilead Sciences Inc. Early in his career Mr. Patel worked at McKinsey & Company serving biotechnology and pharmaceutical clients, and held scientific research positions at ZymoGenetics, Inc. and ProCyte Corporation. He received an undergraduate degree in chemistry from the University of California, Berkeley and a master?s degree in molecular bioengineering/biotechnology from the University of Washington.